Oh, When the Public Comes Marching In
I want to add my voice to those concerned with what might be cast as Myriad Genetics Inc.’s continuing infringement of the public trust, most recently exacerbated by its recent efforts to enforce through the courts its patents for testing BRCA1 and BRCA2. These genetic tests, which grew out of federal funding for University of Utah research, can detect mutations that speak to much higher risks of breast cancer, which can be used, in turn, to take steps that significantly reduce those risks for women. The Myriad genetic tests cost approximately $4,000, and the company is working hard to . . . [more]
